Mayo Clinic Rare and Undiagnosed Disease Hackathon
This study aims to create a special collection of biological samples (biospecimens) and health information (data repository) at Mayo Clinic. This collection will help doctors better understand and diagnose rare and undiagnosed conditions. You might be able to join if you have a rare or undiagnosed condition, have received care at Mayo Clinic, and have had genetic testing that didn't provide a diagnosis. The study is looking to enroll 50 participants. The main goal is to see if it's possible to successfully set up this biospecimen and data collection within one year. The current recruitment status is unclear.
- Study design
- This is an observational study, meaning researchers will collect information without giving any specific treatments. It plans to enroll 50 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study aims to establish the biospecimen and data repository, with feasibility measured at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Mayo Clinic Rare and Undiagnosed Disease Hackathon
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Eric Klee, Ph.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Feasibility of establishing a biospecimen and data repository1 year
Number of enrolled participants who complete all planned repository workflow steps, including eligibility confirmation, informed consent, biospecimen collection, clinical data abstraction, research data generation, and multidisciplinary Hackathon case review.